SEC Info - Ayala Pharmaceuticals, Inc.

SEC Info℠

Home

My Interests

Help

Please Sign In

Ayala Pharmaceuticals, Inc.
NJ
SEC # 1100397

1 Related Registrant:

Click to view...

Registrant

About

Filings

Files

Relationships

Names

Topics

Web

*As Of*	*Filing*	*Page*	*Title*	*Docs.*

3/5/24	DEFM14C	1	Ancillary Agreements With Certain Stockholders of the Company	2
		1	Annex A	2
		1	Annex B	2
		1	Anticipated Accounting Treatment	2
		1	Appraisal Rights	2
		1	Asset Purchase Agreement	2
		1	Asset Purchase Agreement, The	2
2/20/24	PREM14C	1	Asset Sale Consideration, The	1
3/5/24	DEFM14C	1	Asset Sale, The	2
6/23/23	DEF 14A	1	Auditor Ratification Proposal	1
3/5/24	DEFM14C	1	Background of the Asset Sale	2
4/16/24	10-K	1	Business	1
3/5/24	DEFM14C	1	Cautionary Statement Regarding Forward-Looking Statements	2
4/26/24	10-K/A	1	Certain Relationships and Related Transactions, and Director Independence	2
4/16/24	10-K	1	Changes in and Disagreements with Accountants on Accounting and Financial Disclosure	1
11/20/23	10-Q	1	Condensed Consolidated Balance Sheets	3
		1	Condensed Consolidated Financial Statements (Unaudited)	3
		1	Condensed Consolidated Statements of Cash Flows	3
		1	Condensed Consolidated Statements of Operations	3
8/10/23	10-Q	1	Condensed Consolidated Statements of Stockholders' Equity	2
11/20/23	10-Q	1	Condensed Consolidated Statements of Stockholders' Equity (Deficency)	1
3/5/24	DEFM14C	1	Consideration for the Asset Sale	1
4/16/24	10-K	1	Consolidated Balance Sheets	1
		1	Consolidated Statements of Operations	1
		1	Controls and Procedures	4
		1	Cybersecurity	1
11/20/23	10-Q	1	Defaults Upon Senior Securities	3
6/23/23	DEF 14A	1	Director Election Proposal	1
4/26/24	10-K/A	1	Directors, Executive Officers, and Corporate Governance	2
4/16/24	10-K	1	Disclosure Regarding Foreign Jurisdictions That Prevent Inspections	1
4/26/24	10-K/A	1	Executive Compensation	2
6/23/23	DEF 14A	1	Executive Officers and Executive Officer Compensation	1
11/20/23	10-Q	1	Exhibits	3
4/26/24	10-K/A	1	Exhibits and Financial Statement Schedules	2
11/20/23	10-Q	1	Financial Information	3
4/16/24	10-K	1	Financial Statements and Supplementary Data	1
		1	Form 10-K Summary	1
6/23/23	DEF 14A	1	Incentive Plan Amendment Proposal	1
3/5/24	DEFM14C	1	Indemnification of Officers and Directors	2
		1	Interests of Our Directors and Executive Officers in the Asset	2
		1	Interests of Our Directors and Executive Officers in the Asset Sale	2
4/16/24	10-K	1	Legal Proceedings	4
3/5/24	DEFM14C	1	Management Projections Relating to AL102	2
4/16/24	10-K	1	Management's Discussion and Analysis of Financial Condition and Results of Operations	4
		1	Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities	1
3/5/24	DEFM14C	1	Market Price of Our Stock	2
4/16/24	10-K	1	Mine Safety Disclosures	4
11/20/23	10-Q	1	Notes to Condensed Consolidated Financial Statements (Unaudited)	3
4/16/24	10-K	1	Notes to Consolidated Financial Statements	1
3/5/24	DEFM14C	1	Opinion of A.G.P./Alliance Global Partners	2
4/16/24	10-K	1	Other Information	4
		1	Part I	1
		1	Part Ii	1
4/26/24	10-K/A	1	Part Iii	2
		1	Part Iv	2
3/5/24	DEFM14C	1	Parties to the Asset Purchase Agreement, The	2
4/26/24	10-K/A	1	Principal Accounting Fees and Services	2
4/16/24	10-K	1	Properties	1
		1	Quantitative and Qualitative Disclosures About Market Risk	4
6/23/23	DEF 14A	1	Questions and Answers	1
3/5/24	DEFM14C	1	Questions and Answers About the Asset Sale	2
		1	Recommendation of the Board; Reasons for the Asset Sale	2
		1	Regulatory Approvals	2
4/16/24	10-K	1	Report of Independent Registered Public Accounting Firm	1
3/5/24	DEFM14C	1	Required Stockholder Approval for the Asset Sale	1
4/16/24	10-K	1	Reserved	1
		1	Risk Factors	4
6/23/23	DEF 14A	1	Say-On-Pay Proposal	1
3/5/24	DEFM14C	1	Security Ownership of Certain Beneficial Owners and Management	2
4/26/24	10-K/A	1	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	2
11/20/23	10-Q	1	Signatures	3
4/16/24	10-K	1	Statement of Changes in Stockholders' equity	1
		1	Statements of Consolidated Cash Flows	1
3/5/24	DEFM14C	1	Summary Term Sheet	2
		1	The Asset Purchase Agreement	2
		1	The Asset Sale	2
2/20/24	PREM14C	1	The Asset Sale Consideration	1
3/5/24	DEFM14C	1	The Parties to the Asset Purchase Agreement	2
		1	U.S. Federal Income Tax Consequences of the Asset Sale	2
11/20/23	10-Q	1	Unregistered Sales of Equity Securities and Use of Proceeds	3
4/16/24	10-K	1	Unresolved Staff Comments	1
3/5/24	DEFM14C	1	Use of Proceeds	2
6/23/23	DEF 14A	1	Where You Can Find Additional Information	1
3/5/24	DEFM14C	1	Where You Can Find More Information	2

↑Top

Ayala Pharmaceuticals, Inc. NJ SEC # 1100397

162 Topics within the Past Year Past Two Years Past Three Years Past Four Years Past Five Years Entire Database

Ayala Pharmaceuticals, Inc.
NJ
SEC # 1100397

162 Topics
within the